Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors


“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors

The ROS1ders Interview Dr. Ross Camidge (16-May-2019)


On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC


Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Announcing The ROS1ders newsletter “ROS1derings”


We’ve created a newsletter! This newsletter will become a quarterly communication tool for The ROS1ders. In this issue, Marisa Wittebort shares tips for contributing to the ROS1 tissue study, Bärbel Söhlke​ writes about ROS1 activities in Europe, Jeff Wynne details what his data base shows about ROS1 members, and Lisa Goldman offers a fundraising update. … Continue reading Announcing The ROS1ders newsletter “ROS1derings”